All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Biopharmaceutical companies developing cancer therapies had a productive year with about 38% of the record 53 new medicines approved by the FDA targeting oncology indications. This was one of the contributing factors for the 21% growth in the valuation of the price weighted BioWorld Cancer index in 2020.